Koers Sprint Bioscience AB Nasdaq Stockholm
Aandelen
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- | - |
Omzet 2024 * | 118 mln. 10,87 mln. 0 10,13 mln. | Omzet 2025 * | 199 mln. 18,33 mln. 0 17,08 mln. | Marktkapitalisatie | 92,02 mln. 8,47 mln. 0 7,9 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | - | Nettowinst (verlies) 2025 * | - | EV/omzet 2024 * | 0,03 x |
Nettoliquiditeiten 2024 * | 88,2 mln. 8,12 mln. 0 7,57 mln. | Nettoliquiditeiten 2025 * | - 0 - 0 | EV/omzet 2025 * | 0,46 x |
K/w-verhouding 2024 * |
-
| K/w-verhouding 2025 * |
-
| Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 47,2% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Johan Emilsson
CEO | Chief Executive Officer | 40 | 01-10-23 |
Martin Andersson
FOU | Founder | 53 | 01-01-09 |
Director of Finance/CFO | 51 | 01-01-11 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 68 | 01-01-20 | |
Chairman | 56 | 01-01-21 | |
Fredrik Lehmann
BRD | Director/Board Member | 48 | 01-01-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-1,65% | 104 mld. | |
+6,75% | 97,47 mld. | |
+5,71% | 22,25 mld. | |
-12,60% | 21,68 mld. | |
-9,70% | 18,2 mld. | |
-39,98% | 17,02 mld. | |
-10,17% | 16,36 mld. | |
+6,12% | 14,39 mld. | |
+35,47% | 12,37 mld. |